Document is current
Any future updates will be listed below
-
Authors
Carstens, Donna D.
De Backer, Wilfried
Rhodes, Kirsty
Muchmore, Patrick
Lavon, Benjamin R.
Chung, Sze Yan Ernestine
Fogel, Robert
Trudo, Frank
Panettieri, Reynold Jr
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 25 February 2026
Accepted: 15 May 2026
First Online: 15 July 2026
Declarations
Ethics approval and consent to participate: The protocol and any amendments were approved by applicable independent ethics committees or institutional review boards at each participating site and by the appropriate regulatory agency.
Consent for publication: Informed consent for publication was obtained.
Competing interests: DDC, KR, RF, and FT are or were employees or contractors of AstraZeneca at the time of study conduct and reporting and may own stock/stock options. WDB is a medical advisor for FLUIDDA. PM, BRL, and SYEC are employees of FLUIDDA. FLUIDDA received funding from AstraZeneca to conduct this study. RP Jr has received research support from and conducted advisory boards for AstraZeneca, Sanofi, Regeneron, Genentech, and Novartis.
